🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "huge turning point" in the effort against increasingly resistant strains of the pathogen, according to scientists.

A Worldwide Health Concern

Cases of gonorrhoea are on the rise around the world, with figures suggesting more than 82 million infections annually. Notably increased rates are observed in the African continent and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune advancement in the context of growing infection rates, the spread of superbugs and the highly restricted therapeutic options currently available.”

Public health authorities are particularly alarmed about the surge in treatment-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Receive Authorization

One new antibiotic, also known as Nuzolvence, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Experts anticipate that focused deployment of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in close succession. This drug, which is employed against UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to see it through.

“This approval marks a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Research Study Data and Worldwide Availability

As per findings published in a prominent scientific publication, zoliflodacin successfully treated more than 90% of uncomplicated infections. This places it at an similar efficacy with the current standard treatment, which involves a dual-drug approach. The research involved hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the authority to register and commercialise the drug in numerous regions with limited resources.

Medical professionals directly involved have voiced hope. Access to a one-pill regimen of this kind is described as a "critical tool" for public health efforts. This is viewed as essential to reduce the burden of the disease for patients and to stop the proliferation of extremely resistant gonorrhoea around the world.